Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Endothelial Microvesicles and Soluble Markers of Endothelial Injury in Critically Ill Newborns

V. Vítková, M. Pánek, P. Janec, M. Šibíková, V. Vobruba, M. Haluzík, J. Živný, J. Janota,

. 2018 ; 2018 (-) : 1975056. [pub] 20180719

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000452

Grantová podpora
NV16-27800A MZ0 CEP - Centrální evidence projektů

Neonatal systemic inflammatory response and multiple organ dysfunction syndrome are the main postnatal insults influencing mortality and morbidity. Critically ill newborns with high predicted mortality are supported by extracorporeal membrane oxygenation (ECMO). Biomarkers of inflammatory response and endothelial injury can be used for early diagnosis and treatment of critical neonatal situations. The aim of our study was to explore plasma proteins and endothelial microvesicles as markers of inflammation and endothelial activation in newborns on ECMO and to compare them with healthy neonates. Thirteen newborns on ECMO and 13 healthy newborns were included in the study. Plasma soluble biomarkers were measured using multiplex immunoassay based on Luminex® xMAP multianalyte profiling platform. The total microvesicle count and plasma level of surface antigen-specific microvesicles were determined by flow cytometry. The plasma concentration of cell-derived microvesicles was measured using annexin-V labeling, and the endothelial origin of microvesicles was determined using lineage-specific antigen labeling of endothelial cell/microvesicle markers (endoglin/CD105, PECAM1/CD31, VEGFR2/CD309, and MadCAM1). Inflammatory markers (procalcitonin, IL-1β, IL-6, and IL-22) were increased in the ECMO group (P < 0.01). The assessment of endothelial markers showed higher concentrations of endocan and angiopoietin-2 (P < 0.01) in the ECMO group while VEGF in the ECMO group was significantly lower (P < 0.01). In the ECMO group, the concentration of annexin-V-positive microvesicles (total microvesicles) and endothelial microvesicles expressing mucosal vascular addressin cell adhesion molecule 1 (MadCAM1) was increased (P = 0.05). In summary, we found increased concentrations of soluble inflammatory and endothelial markers in the plasma of critically ill newborns with multiple organ dysfunction. Increased plasma concentrations of microvesicles may reflect the activation or damage of blood cells and vasculature including endothelial cells. The measurement of cell membrane-derived microvesicles may be added to the panel of established inflammatory markers in order to increase the sensitivity and specificity of the diagnostic process in critically ill newborns.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000452
003      
CZ-PrNML
005      
20200128105711.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2018/1975056 $2 doi
035    __
$a (PubMed)30116143
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vítková, Veronika $u Department of Neonatology, Thomayer Hospital Prague, Videnska 800, 14059 Praha 4, Czech Republic. Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Praha 2, Czech Republic.
245    10
$a Endothelial Microvesicles and Soluble Markers of Endothelial Injury in Critically Ill Newborns / $c V. Vítková, M. Pánek, P. Janec, M. Šibíková, V. Vobruba, M. Haluzík, J. Živný, J. Janota,
520    9_
$a Neonatal systemic inflammatory response and multiple organ dysfunction syndrome are the main postnatal insults influencing mortality and morbidity. Critically ill newborns with high predicted mortality are supported by extracorporeal membrane oxygenation (ECMO). Biomarkers of inflammatory response and endothelial injury can be used for early diagnosis and treatment of critical neonatal situations. The aim of our study was to explore plasma proteins and endothelial microvesicles as markers of inflammation and endothelial activation in newborns on ECMO and to compare them with healthy neonates. Thirteen newborns on ECMO and 13 healthy newborns were included in the study. Plasma soluble biomarkers were measured using multiplex immunoassay based on Luminex® xMAP multianalyte profiling platform. The total microvesicle count and plasma level of surface antigen-specific microvesicles were determined by flow cytometry. The plasma concentration of cell-derived microvesicles was measured using annexin-V labeling, and the endothelial origin of microvesicles was determined using lineage-specific antigen labeling of endothelial cell/microvesicle markers (endoglin/CD105, PECAM1/CD31, VEGFR2/CD309, and MadCAM1). Inflammatory markers (procalcitonin, IL-1β, IL-6, and IL-22) were increased in the ECMO group (P < 0.01). The assessment of endothelial markers showed higher concentrations of endocan and angiopoietin-2 (P < 0.01) in the ECMO group while VEGF in the ECMO group was significantly lower (P < 0.01). In the ECMO group, the concentration of annexin-V-positive microvesicles (total microvesicles) and endothelial microvesicles expressing mucosal vascular addressin cell adhesion molecule 1 (MadCAM1) was increased (P = 0.05). In summary, we found increased concentrations of soluble inflammatory and endothelial markers in the plasma of critically ill newborns with multiple organ dysfunction. Increased plasma concentrations of microvesicles may reflect the activation or damage of blood cells and vasculature including endothelial cells. The measurement of cell membrane-derived microvesicles may be added to the panel of established inflammatory markers in order to increase the sensitivity and specificity of the diagnostic process in critically ill newborns.
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a buněčná membrána $x metabolismus $7 D002462
650    _2
$a mikropartikule $x metabolismus $7 D055252
650    _2
$a kritický stav $7 D016638
650    _2
$a endoteliální buňky $7 D042783
650    _2
$a endotel $x metabolismus $7 D004727
650    12
$a mimotělní membránová oxygenace $7 D015199
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a zánět $x krev $7 D007249
650    _2
$a mužské pohlaví $7 D008297
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pánek, Martin, $d 1974- $7 mzk2006337208 $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Praha 2, Czech Republic. Department of Neonatology, Masaryk Hospital Usti nad Labem, Krajska zdravotni, Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic.
700    1_
$a Janec, Petr $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Praha 2, Czech Republic. Department of Neonatology, Masaryk Hospital Usti nad Labem, Krajska zdravotni, Socialni pece 3316/12A, 40113 Usti nad Labem, Czech Republic.
700    1_
$a Šibíková, Michaela $7 xx0237022 $u Third Faculty of Medicine, Charles University, Ruska 87, 10000 Praha 10, Czech Republic.
700    1_
$a Vobruba, Václav $u Department of Pediatrics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Ke Karlovu 2, 121 00 Praha 2, Czech Republic.
700    1_
$a Haluzík, Martin $u The Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Kateřinská 32, 12853 Praha 2, Czech Republic.
700    1_
$a Živný, Jan $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Praha 2, Czech Republic.
700    1_
$a Janota, Jan $u Department of Neonatology, Thomayer Hospital Prague, Videnska 800, 14059 Praha 4, Czech Republic. Institute of Pathological Physiology, First Faculty of Medicine, Charles University, U Nemocnice 5, 12853 Praha 2, Czech Republic.
773    0_
$w MED00006378 $t Mediators of inflammation $x 1466-1861 $g Roč. 2018, č. - (2018), s. 1975056
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30116143 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20200128110052 $b ABA008
999    __
$a ok $b bmc $g 1363847 $s 1038575
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 2018 $c - $d 1975056 $e 20180719 $i 1466-1861 $m Mediators of inflammation $n Mediators Inflamm $x MED00006378
GRA    __
$a NV16-27800A $p MZ0
LZP    __
$a Pubmed-20190107
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace